Corient Private Wealth LLC Has $3.10 Million Stock Position in Sana Biotechnology, Inc. $SANA

Corient Private Wealth LLC lifted its stake in shares of Sana Biotechnology, Inc. (NASDAQ:SANA) by 264.7% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,136,000 shares of the company’s stock after acquiring an additional 824,505 shares during the quarter. Corient Private Wealth LLC owned approximately 0.48% of Sana Biotechnology worth $3,101,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds have also added to or reduced their stakes in the company. Nisa Investment Advisors LLC boosted its stake in Sana Biotechnology by 673.8% during the second quarter. Nisa Investment Advisors LLC now owns 10,911 shares of the company’s stock worth $30,000 after acquiring an additional 9,501 shares in the last quarter. Hoey Investments Inc. acquired a new position in shares of Sana Biotechnology during the second quarter valued at about $33,000. BNP Paribas Financial Markets lifted its position in shares of Sana Biotechnology by 46.9% during the second quarter. BNP Paribas Financial Markets now owns 15,444 shares of the company’s stock valued at $42,000 after purchasing an additional 4,931 shares in the last quarter. Captrust Financial Advisors boosted its stake in shares of Sana Biotechnology by 43.8% in the 2nd quarter. Captrust Financial Advisors now owns 15,793 shares of the company’s stock worth $43,000 after buying an additional 4,807 shares during the last quarter. Finally, Good Life Advisors LLC purchased a new stake in shares of Sana Biotechnology during the second quarter valued at approximately $46,000. Institutional investors and hedge funds own 88.23% of the company’s stock.

Analysts Set New Price Targets

SANA has been the subject of several analyst reports. HC Wainwright reduced their price objective on shares of Sana Biotechnology from $11.00 to $9.00 and set a “buy” rating for the company in a research note on Friday, November 7th. Weiss Ratings reissued a “sell (d-)” rating on shares of Sana Biotechnology in a report on Monday, December 8th. Citigroup restated an “outperform” rating on shares of Sana Biotechnology in a research report on Thursday, October 30th. Wall Street Zen upgraded shares of Sana Biotechnology from a “sell” rating to a “hold” rating in a research report on Saturday. Finally, JMP Securities set a $8.00 target price on Sana Biotechnology in a research note on Thursday, October 30th. Eight analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Sana Biotechnology presently has an average rating of “Moderate Buy” and a consensus price target of $8.33.

Sana Biotechnology Trading Down 3.1%

Sana Biotechnology stock opened at $4.36 on Monday. The firm has a 50 day moving average of $4.54 and a 200 day moving average of $3.85. The firm has a market capitalization of $1.16 billion, a price-to-earnings ratio of -4.49 and a beta of 1.95. Sana Biotechnology, Inc. has a 12-month low of $1.26 and a 12-month high of $7.30.

Sana Biotechnology (NASDAQ:SANA) last posted its quarterly earnings results on Thursday, November 6th. The company reported ($0.15) EPS for the quarter, beating analysts’ consensus estimates of ($0.18) by $0.03. On average, analysts predict that Sana Biotechnology, Inc. will post -1.16 EPS for the current year.

Sana Biotechnology Company Profile

Sana Biotechnology is a clinical-stage biopharmaceutical company focused on the development of engineered cells as medicines with the goal of treating a broad range of diseases. The company applies advanced gene editing and gene delivery technologies to create next-generation cell therapy products for oncology, genetic disorders and other serious diseases. By leveraging both ex vivo and in vivo approaches, Sana aims to repair or replace damaged cells and restore healthy tissue function.

The company’s core platform integrates proprietary gene writing capabilities alongside established gene editing tools such as CRISPR–Cas9.